Glenmark Pharmaceuticals Limited has launched new diabetes medicine of fixed-dose combination (FDC) to contain Teneligliptin with Pioglitazone. The brand name Zita Plus Pio has Teneligliptin (20 mg) + Pioglitazone (15 mg) to be taken once a day. The only DPP4 and Glitazone combination brand in India is for adults with uncontrolled Type 2 diabetes.

• Aditya Birla Capital Shares Jump 4% on Gold Loan Foray
• Crompton Greaves Shares Rise on FY29-31 Outlook
• Escorts Kubota to Invest Rs 2,000 Crore in New UP Plant
• Brigade Enterprises Shares Jump 6% on HealthEdge Lease Deal
• Dhoot Transmission Hits 52-Week High, Stock Up 70% From IPO

“Diabetes is a key area of focus for Glenmark, a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients,” said Alok Malik, Group Vice President & Head, India, Founder of Glenmark Pharmaceutical.

Fixed-Dose Combination (FDC) is innovated by Glenmark and is approved by DCGI (Drug Controller General of India). The drug named Teneliglitptin with Pioglitazone will be helpful for diabetes patients, which improves glycemic control reducing Insulin Resistance.